Metabolism of the new liposomal anticancer drug N4-octadecyl-1-β-D arabinofuranosylcytosine in mice

Drug Metabolism and Disposition

Volumn 27, Issue 3, 1999, Pages 342-350

  Koller Lucae, Sibylle K M ^a   Suter, Marc J F ^b   Rentsch, Katharina M ^c   Schott, Herbert ^d   Schwendener, Reto A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b SWISS FEDERAL INSTITUTE OF AQUATIC SCIENCE AND TECHNOLOGY   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d University Hospital Department of Pathology Division of Cancer Research ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE DERIVATIVE; LIPOSOME; N4 OCTADECYL 1 BETA DEXTRO ARABINOFURANOSYCYTOSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG EXCRETION; DRUG FECES LEVEL; DRUG FORMULATION; DRUG METABOLISM; DRUG SCREENING; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; LIVER METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA; ARA; TRITIUM;

EID: 0032911243     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. 4-acyl-1-β-D-arabinofuranosylcytosine. Cancer Res 56:2726-2732.
2. Berdel WE, Okamoto S, Danhauser Riedl S, Hong CI, Winton EF, West CR, Rastetter J and Vogler WR (1989) Therapeutic activity of 1-β-D-arabinofuranosylcytosine conjugates of lipids in WEHI-3B leukemia in mice. Exp Hematol 17:364-367.
3. Boucher JL, Delaforge M, Salaun JP, Pinot F, Durst F, Pflieger P and Mioskowski C (1996) In vitro hydroxylation and epoxidation of some isomeric lauric acid analogs by rat liver microsomes. Identification of metabolites and effects of clofibrate or phenobarbital pretreatment. Drug Metab Dispos 24:462-468.
4. Breithaupt H and Schick J (1981) Determination of cytarabine and uracil arabinoside in human plasma and cerebrospinal fluid by high-performance liquid chromatography. J Chromatogr 225:99-106.
5. Dedrick RL, Forrester DD, Cannon JN, El Dareer DS and Mellett LB (1973) Pharmacokinetics of 1-β-D-arabinofuranosylcytosine (ara-C) deamination in several species. Biochem Pharmacol 22:2405-2417.
6. Gahrton G (1983) Treatment of acute leukemia - advances in chemotherapy, immunotherapy and bone marrow transplantation. Adv Cancer Res 40:255-329.
7. Ho DH (1973) Distribution of kinase and deaminase of 1-β-D-arabinofuranosylcytosine in tissues of man and mouse. Cancer Res 33:2816-2820.
8. Ho DH and Frei E (1971) Clinical pharmacology of 1-β-D-arabinofuranosylcytosine. Clin Pharmacol Ther 12:944-954.
9. Ho DHW and Neil GL (1977) Pharmacology of 5′-esters of 1-β-D-arabinofuranosylcytosine. Cancer Res 37:1640-1643.
10. 4-hexadecyl-1-β-D-arabinofuranosylcytosine, a lipophilic derivative of 1-β-D-arabinofuranosylcytosine. Br J Cancer 71:957-962.
11. 4-hexadecyl-1-β-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937. Cancer Chemother Pharmacol 36:483-492.
12. 4-hexadecyl-1-β-D-arabinofuranosyl-cytosine. Br J Cancer 72:1067-1073.
13. 4-substituted 2,2′-anhydronucleosides. J Med Chem 17:1076-1078.
14. Keating MJ, McCredie KB, Bodey GP, Smith TL, Gehan E and Freireich EJ (1982) Improved prospects for long-term survival in adults with acute myelogenous leukemia. J Am Med Assoc 248:2481-2486.
15. Kodama K, Morozumi M, Saitoh K, Kuninaka A, Yoshino H and Saneyoshi M (1989) Antitumor activity and pharmacology of 1-β-D-arabinofuranosylcyiosine-5′-stearylphosphate: An orally active derivative of 1-β-D-arabinofuranosylcytosine. Jpn J Cancer Res 80:679-685.
16. 4-octadecyl-1-β-D-arabinofuranosylcytosine, a new anticancer drug. J Pharmacol Exp Ther 282:1572-1580.
17. 4-behenoyl-1-β-D-arabinofuranosylcytosine, in mice and its biological significance. Cancer Res 41:2501-2506.
18. 4-palmitoyl-1-β-D-arabinofuranosylcytosine. Med Oncol Tumor Pharmacother 4:67-73.
19. Plunkett W and Gandhi V (1993) Cellular pharmacodynamics of anticancer drugs. Semin Oncol 20:30-63.
20. 4-octadecyl-1-β-D-arabinofuranosylcytosine in plasma and erythrocytes. J Chromatogr B Biomed Appl 673:259-266.
21. Rognstad R (1995) On the estimation of alternative pathways of fatty acid oxidation in the liver in vivo. Bull Math Biol 57:191-203.
22. 4-acyl and 2,2′-anhydro-3′-O-acyl derivatives as potential prodrugs. J Med Chem 25:171-178.
23. Schleyer E, Braess J, Ramsauer B, Unterhalt M, Kaufmann C, Wilde S, Schussler M and Hiddemann W (1995) Pharmacokinetics of ara-CMP-Stearate (YNK01): Phase 1 study of the oral ara-C derivative. Leukemia 9:1085-1090.
24. Schott H, Häussler MP and Schwendener RA (1994) Synthese von 4-Alkylcytosinnucleosiden und deren cytostatische Wirkung im L1210 Leukämiemodell der Maus. Liebigs Ann Chem 1994:465-470.
25. 4-alkyl derivatives of 1-β-D-arabinofuranosylcytosine. J Cancer Res Clin Oncol 122:102-108.
26. 4-octadecyl-ara-C, NOAC. Drugs Future 20:11-15.
27. 4-octadecyl-1-β-D-arabinofuranosylcytosine in liposomal preparations. J Liposome Res 5:27-47.
28. Storch J, Herr FM, Hsu KT, Kim HK, Liou HL and Smith ER (1996) The role of membranes and intracellular binding proteins in cytoplasmic transport of hydrophobic molecules: Fatty acid-binding proteins. Comp Biochem Physiol B 115:333-339.
29. Szinai I and De Clercq E (1989) Biotransformation of 5-(2-chloroethyl)-2′-deoxyuridine in male NMR1 mice. Drug Metab Dispos 17:683-689.
30. Testa B and Jenner P (1976) Oxidative N-dealkylation, in Drug Metabolism: Chemical and Biochemical Aspects (Swarbrick J ed) pp 82-97, Marcel Dekker, New York.
31. 4-acyl derivatives of 1-β-D-arabinofuranosylcytosine in the mouse liver microsome. Cancer Res 42:2250-2254.
32. Ueda T, Kamiya K, Urasaki Y, Wataya S, Kawai Y, Tsutani H, Sugiyama M and Nakamura T (1994) Clinical pharmacology of 1-β-D-arabinofuranosylcytosine-5′-stearylphosphate, an orally administered long-acting derivative of low-dose 1-β-D-arabinofuranosylcytosine. Cancer Res 54:109-113.
33. 4-substituted derivatives of 1-β-D-arabinofuranosylcytosine and -5-fluorocytosine. J Med Chem 11:144-148.
34. 16, a metabolite of the cytosine arabinoside prodrug, YNKO1, in rat liver. Biochem Pharmacol 39:1505-1512.